{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:26:19Z","timestamp":1783031179671,"version":"3.54.6"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Treosulfan and fludarabine (Treo\/Flu) were successfully introduced into toxicity-reduced conditioning for SCT. However, the risk of post-SCT relapse remains a matter of concern. We report the results of a novel individual treatment approach with Treo\/Flu and cytarabine (Treo\/Flu\/AraC) conditioning prior to allogeneic SCT in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p> Seventy-seven patients (median age 54 years) at high risk of disease relapse due to unfavorable cytogenetics or failure to achieve complete remission prior to SCT were included. Median follow-up was 3.2 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 1-, 2- and 3-year RFS rates were 49.4%, 41.7%, and 37.6% and OS rates were 59.3%, 49.3%, and 45.4%, respectively. Cumulative incidence of NRM was 10% at 100 days, 18.8% at 1 year and 20.1% at 2 years. The cumulative incidence of relapse increased from 31% at 1 year to 38.5% after 3 years. The cumulative incidences of engraftment, chimerism, graft-versus-host disease (GvHD) and toxicities were acceptable and comparable with similar patients conditioned with Treo\/Flu or FLAMSA-RIC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p> In conclusion, Treo\/Flu\/AraC provides tolerable, feasible, and effective conditioning for patients with AML, MDS or MPN, even in advanced disease states. The incidence of NRM and relapse is acceptable in this heavily pre-treated population with high-risk disease. Future research will aim to confirm these initial findings and include a larger number of participants in a prospective trial.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03836-8","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T10:05:04Z","timestamp":1634810704000},"page":"2599-2609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms"],"prefix":"10.1007","volume":"148","author":[{"given":"Samantha","family":"O\u2018Hagan Henderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-8059","authenticated-orcid":false,"given":"Jochen J.","family":"Frietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Henning","family":"K\u00f6hne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Casper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"issue":"1","key":"3836_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-015-0201-x","volume":"8","author":"Y Arai","year":"2015","unstructured":"Arai Y, Aoki K, Takeda J, Kondo T, Eto T, Ota S et al (2015) Clinical significance of high-dose cytarabine added to cyclophosphamide\/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy. J Hematol Oncol 8(1):102. https:\/\/doi.org\/10.1186\/s13045-015-0201-x","journal-title":"J Hematol Oncol"},{"issue":"9","key":"3836_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ajh.21240","volume":"83","author":"D Baronciani","year":"2008","unstructured":"Baronciani D, Rambaldi A, Iori AP, Di Bartolomeo P, Pilo F, Pettinau M et al (2008) Treosulfan\/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol 83(9):717\u2013720. https:\/\/doi.org\/10.1002\/ajh.21240","journal-title":"Am J Hematol"},{"issue":"3","key":"3836_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.bmt.1704784","volume":"35","author":"DW Beelen","year":"2005","unstructured":"Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME et al (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35(3):233\u2013241. https:\/\/doi.org\/10.1038\/sj.bmt.1704784","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3836_CR4","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Remenyi P et al (2020) Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol 7(1):e28\u2013e39. https:\/\/doi.org\/10.1016\/S2352-3026(19)30157-7","journal-title":"Lancet Haematol"},{"issue":"2","key":"3836_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bmt.2015.238","volume":"51","author":"S Ben-Barouch","year":"2016","unstructured":"Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R (2016) Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant 51(2):232\u2013240. https:\/\/doi.org\/10.1038\/bmt.2015.238","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3836_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/BF00194527","volume":"14","author":"RL Capizzi","year":"1996","unstructured":"Capizzi RL (1996) Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Invest New Drugs 14(3):249\u2013256. https:\/\/doi.org\/10.1007\/BF00194527","journal-title":"Invest New Drugs"},{"issue":"11","key":"3836_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.5414\/cpp42661","volume":"42","author":"J Casper","year":"2004","unstructured":"Casper J, Freund M (2004) Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther 42(11):661\u2013662. https:\/\/doi.org\/10.5414\/cpp42661","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"3836_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","volume":"103","author":"J Casper","year":"2004","unstructured":"Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U et al (2004a) Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103(2):725\u2013731. https:\/\/doi.org\/10.1182\/blood-2002-11-3615","journal-title":"Blood"},{"issue":"Suppl 1","key":"3836_CR9","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1007\/s00277-004-0850-2","volume":"83","author":"J Casper","year":"2004","unstructured":"Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H et al (2004b) Treosulfan\/fludarabine: a new conditioning regimen in allogeneic transplantation. Ann Hematol 83(Suppl 1):S70\u2013S71. https:\/\/doi.org\/10.1007\/s00277-004-0850-2","journal-title":"Ann Hematol"},{"issue":"20","key":"3836_CR10","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1200\/JCO.2009.23.3429","volume":"28","author":"J Casper","year":"2010","unstructured":"Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L et al (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan\/fludarabine conditioning. J Clin Oncol 28(20):3344\u20133351. https:\/\/doi.org\/10.1200\/JCO.2009.23.3429","journal-title":"J Clin Oncol"},{"issue":"9","key":"3836_CR11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/bmt.2011.242","volume":"47","author":"J Casper","year":"2012","unstructured":"Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T et al (2012) Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning. Bone Marrow Transplant 47(9):1171\u20131177. https:\/\/doi.org\/10.1038\/bmt.2011.242","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"3836_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","volume":"25","author":"S Corbacioglu","year":"2019","unstructured":"Corbacioglu S, Jabbour EJ, Mohty M (2019) Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant 25(7):1271\u20131280. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"3836_CR13","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.bbmt.2017.12.785","volume":"24","author":"HJ Deeg","year":"2018","unstructured":"Deeg HJ, Stevens EA, Salit RB, Ermoian RP, Fang M, Gyurkocza B et al (2018) Transplant conditioning with treosulfan\/fludarabine with or without total body irradiation: a randomized phase II trial in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant 24(5):956\u2013963. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.785","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3836_CR14","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al (1996) Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17(2):225\u2013230","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3836_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"12","key":"3836_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945\u2013956. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3836_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","volume":"41","author":"V Gandhi","year":"2002","unstructured":"Gandhi V, Plunkett W (2002) Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41(2):93\u2013103. https:\/\/doi.org\/10.2165\/00003088-200241020-00002","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3836_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","volume":"11","author":"V Gandhi","year":"1993","unstructured":"Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11(1):116\u2013124. https:\/\/doi.org\/10.1200\/JCO.1993.11.1.116","journal-title":"J Clin Oncol"},{"issue":"4","key":"3836_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbmt.2014.01.009","volume":"20","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A et al (2014) Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant 20(4):549\u2013555. https:\/\/doi.org\/10.1016\/j.bbmt.2014.01.009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3836_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U et al (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant 22(1):4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3836_CR21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/bmt.2010.153","volume":"46","author":"I Hilgendorf","year":"2011","unstructured":"Hilgendorf I, Wolff D, Gromke T, Trenschel R, Elmaagacli AH, Pichlmeier U et al (2011) Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. Bone Marrow Transplant 46(4):502\u2013509. https:\/\/doi.org\/10.1038\/bmt.2010.153","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3836_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1750-1172-2-35","volume":"2","author":"DA Jacobsohn","year":"2007","unstructured":"Jacobsohn DA, Vogelsang GB (2007) Acute graft versus host disease. Orphanet J Rare Dis 2(1):35. https:\/\/doi.org\/10.1186\/1750-1172-2-35","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"3836_CR23","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00277-013-1790-5","volume":"92","author":"M Krejci","year":"2013","unstructured":"Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M et al (2013) Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Ann Hematol 92(10):1397\u20131403. https:\/\/doi.org\/10.1007\/s00277-013-1790-5","journal-title":"Ann Hematol"},{"issue":"4","key":"3836_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.bmt.1705259","volume":"37","author":"N Kroger","year":"2006","unstructured":"Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F et al (2006) Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 37(4):339\u2013344. https:\/\/doi.org\/10.1038\/sj.bmt.1705259","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"3836_CR25","first-page":"935","volume":"91","author":"A Larocca","year":"2006","unstructured":"Larocca A, Piaggio G, Podesta M, Pitto A, Bruno B, Di Grazia C et al (2006) Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 91(7):935\u2013940","journal-title":"Haematologica"},{"issue":"2","key":"3836_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.bbmt.2016.11.002","volume":"23","author":"F Malard","year":"2017","unstructured":"Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J et al (2017) sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with intermediate- or high-risk acute myeloid leukemia in complete remission: a study from the acute leukemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant 23(2):278\u2013284. https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"3836_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12185-012-1192-9","volume":"96","author":"B McLaughlin","year":"2012","unstructured":"McLaughlin B, Im A, Raptis A, Agha M, Hou JZ, Redner R et al (2012) Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. Int J Hematol 96(6):743\u2013747. https:\/\/doi.org\/10.1007\/s12185-012-1192-9","journal-title":"Int J Hematol"},{"issue":"8","key":"3836_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00277-012-1429-y","volume":"91","author":"M Michallet","year":"2012","unstructured":"Michallet M, Sobh M, Milpied N, Bay JO, Furst S, Harousseau JL et al (2012) Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10\/10 HLA-identical unrelated donor. Ann Hematol 91(8):1289\u20131297. https:\/\/doi.org\/10.1007\/s00277-012-1429-y","journal-title":"Ann Hematol"},{"issue":"5","key":"3836_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00280-007-0669-3","volume":"62","author":"D Munkelt","year":"2008","unstructured":"Munkelt D, Koehl U, Kloess S, Zimmermann SY, Kalaaoui RE, Wehner S et al (2008) Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol 62(5):821\u2013830. https:\/\/doi.org\/10.1007\/s00280-007-0669-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"3836_CR30","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/cncr.30646","volume":"123","author":"A Nagler","year":"2017","unstructured":"Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A et al (2017) Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the acute leukemia working party of the european society for blood and marrow transplantation. Cancer 123(14):2671\u20132679. https:\/\/doi.org\/10.1002\/cncr.30646","journal-title":"Cancer"},{"issue":"4","key":"3836_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/bmt.2012.239","volume":"48","author":"R Olsson","year":"2013","unstructured":"Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J et al (2013) Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant 48(4):537\u2013543. https:\/\/doi.org\/10.1038\/bmt.2012.239","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3836_CR32","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/leu.2015.75","volume":"29","author":"RF Olsson","year":"2015","unstructured":"Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ et al (2015) Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia 29(8):1754\u20131762. https:\/\/doi.org\/10.1038\/leu.2015.75","journal-title":"Leukemia"},{"issue":"22","key":"3836_CR33","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1182\/blood.V128.22.5855.5855","volume":"128","author":"H Patel","year":"2016","unstructured":"Patel H, Molina A, Nikanjam M, Schiller GJ (2016) Risk factors for relapse following allogeneic transplant for acute myeloid leukemia in the UCLA patient population. Blood 128(22):5855. https:\/\/doi.org\/10.1182\/blood.V128.22.5855.5855","journal-title":"Blood"},{"issue":"1","key":"3836_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00432-015-2050-y","volume":"142","author":"C Pfrepper","year":"2016","unstructured":"Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M et al (2016) Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. J Cancer Res Clin Oncol 142(1):317\u2013324. https:\/\/doi.org\/10.1007\/s00432-015-2050-y","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"3836_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12185-017-2320-3","volume":"106","author":"M Remberger","year":"2017","unstructured":"Remberger M, Torlen J, Serafi IE, Garming-Legert K, Bjorklund A, Ljungman P et al (2017) Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. Int J Hematol 106(4):471\u2013475. https:\/\/doi.org\/10.1007\/s12185-017-2320-3","journal-title":"Int J Hematol"},{"issue":"11","key":"3836_CR36","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","volume":"26","author":"E Rodriguez-Arboli","year":"2020","unstructured":"Rodriguez-Arboli E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J et al (2020) FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed\/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant 26(11):2165\u20132173. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"3836_CR37","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","volume":"96","author":"T Ruutu","year":"2011","unstructured":"Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M et al (2011) Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica 96(9):1344\u20131350. https:\/\/doi.org\/10.3324\/haematol.2011.043810","journal-title":"Haematologica"},{"issue":"1","key":"3836_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbmt.2013.10.014","volume":"20","author":"T Ruutu","year":"2014","unstructured":"Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J et al (2014) Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant 20(1):135\u2013138. https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3836_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346. https:\/\/doi.org\/10.1016\/0197-2456(96)00075-x","journal-title":"Control Clin Trials"},{"issue":"11","key":"3836_CR40","first-page":"4209","volume":"6","author":"ME Scheulen","year":"2000","unstructured":"Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM et al (2000) Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6(11):4209\u20134216","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3836_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/sj.bmt.1705605","volume":"39","author":"M Schmidt-Hieber","year":"2007","unstructured":"Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H et al (2007) Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 39(7):389\u2013396. https:\/\/doi.org\/10.1038\/sj.bmt.1705605","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3836_CR42","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00277-013-1774-5","volume":"92","author":"D Schneidawind","year":"2013","unstructured":"Schneidawind D, Federmann B, Faul C, Vogel W, Kanz L, Bethge WA (2013) Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia. Ann Hematol 92(10):1389\u20131395. https:\/\/doi.org\/10.1007\/s00277-013-1774-5","journal-title":"Ann Hematol"},{"issue":"11","key":"3836_CR43","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL et al (2017) Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 35(11):1154\u20131161. https:\/\/doi.org\/10.1200\/JCO.2016.70.7091","journal-title":"J Clin Oncol"},{"issue":"4","key":"3836_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381\u2013387. https:\/\/doi.org\/10.1038\/sj.bmt.1705727","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3836_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41409-018-0288-0","volume":"54","author":"V Sheth","year":"2019","unstructured":"Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A et al (2019) Comparison of FLAMSA-based reduced intensity conditioning with treosulfan\/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP\/EBMT analysis. Bone Marrow Transplant 54(4):531\u2013539. https:\/\/doi.org\/10.1038\/s41409-018-0288-0","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"3836_CR46","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/blood.V116.21.3473.3473","volume":"116","author":"A Shimoni","year":"2010","unstructured":"Shimoni A, Rand A, Shem-Tov N, Hardan I, Volchek Y, Yerushalmi R et al (2010) Fludarabine and treosulfan conditioning for allogeneic stem-cell transplantation; a dose-intense regimen with limited toxicity. Blood 116(21):3473. https:\/\/doi.org\/10.1182\/blood.V116.21.3473.3473","journal-title":"Blood"},{"issue":"1","key":"3836_CR47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-016-0347-1","volume":"9","author":"A Shimoni","year":"2016","unstructured":"Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J et al (2016) Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol 9(1):118. https:\/\/doi.org\/10.1186\/s13045-016-0347-1","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3836_CR48","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.bbmt.2017.12.776","volume":"24","author":"A Shimoni","year":"2018","unstructured":"Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufti G et al (2018) Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the acute leukemia working party of european society for blood and marrow transplantation. Biol Blood Marrow Transplant 24(4):751\u2013757. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.776","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3836_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.exphem.2005.09.015","volume":"34","author":"F Sjoo","year":"2006","unstructured":"Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M et al (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 34(1):115\u2013121. https:\/\/doi.org\/10.1016\/j.exphem.2005.09.015","journal-title":"Exp Hematol"},{"issue":"1","key":"3836_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199907013410103","volume":"341","author":"G Socie","year":"1999","unstructured":"Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al (1999) Long-term survival and late deaths after allogeneic bone marrow transplantation. Late effects working committee of the international bone marrow transplant registry. N Engl J Med 341(1):14\u201321. https:\/\/doi.org\/10.1056\/NEJM199907013410103","journal-title":"N Engl J Med"},{"issue":"8","key":"3836_CR51","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"21","key":"3836_CR52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood.V120.21.469.469","volume":"120","author":"M Stern","year":"2012","unstructured":"Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M et al (2012) Impact of graft-versus-host disease on relapse after allogeneic hematopoietic stem cell transplantation, an EBMT Megafile study. Blood 120(21):469. https:\/\/doi.org\/10.1182\/blood.V120.21.469.469","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03836-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:12:32Z","timestamp":1663056752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03836-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3836"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03836-8","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH declares no competing interests. IH received speaker fees from Novartis and Jazz and travel support from Medac, Novartis, and Celgene. JF declares no competing interests. AH declares research support from Novartis, BMS, Pfizer and Incyte. C-HK declares honoraria, travel, accommodation and expenses from Bristol-Myers Squibb, Merck, Pfizer, Sanofi, and Servier. JC declares honoraria, travel, accommodation, and expenses from Medac and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}